Effect Of Treatment With Dapagliflozin According To Baseline Systolic Blood Pressure In Patients With Hfref: An Analysis Of The Dapa-Hf Trial

In DAPA-HF, dapagliflozin (10mg qd), vs. placebo, reduced the risk of worsening HF and CV death. Because low systolic BP is common in HFrEF, leads to under-treatment and is associated with worse outcomes, we assessed the efficacy and safety of dapagliflozin across baseline SBP in DAPA-HF. Key